January 10, 2024 Labcorp's Clinical Development and Commercialization Services business is now Fortrea (NASDAQ: FTRE). ©2023 Fortrea Inc. All rights reserved. Confidential. 42nd Annual J.P. Morgan Healthcare Conference Fortrea Tom Pike, Chief Executive Officer & Chairman of the Board Jill McConnell, Chief Financial Officer FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Labcorp's Clinical Development and Commercialization Services business is now Fortrea (NASDAQ: FTRE). ©2023 Fortrea Inc. All right ...

LOS ANGELES, June 16, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 1, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR FORTREA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS T ...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

NEW YORK, June 16, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE).Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152955&from=4CLASS PERIOD: July 3, 202 ...

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

Core Insights - Regentis Group is a student-run equity research firm that emphasizes fresh perspectives to unlock insights in investment analysis [1] - The firm is founded and operated by high-performing university students passionate about finance, aiming to redefine the future of investment analysis [1] - Regentis specializes in fundamentals-driven equity research across various sectors, combining academic excellence with practical application [1] Unique Attributes - The firm distinguishes itself through its youthful edge, intellectual curiosity, and commitment to quality [1] - Analysts at Regentis are trained to think independently and challenge conventional narratives, delivering high-conviction ideas supported by rigorous models and data [1] - Regentis aims to build a new approach to equity research grounded in integrity, precision, and a long-term perspective [1] Target Audience - Regentis caters to both seasoned investors and learners, providing a bold and thoughtful voice in the investment community [1] - The firm positions itself as a movement of next-generation thinkers in the field of investment analysis [1]

Core Insights - QIAGEN N.V. (QGEN) is positioned for growth due to significant investments in R&D for expanding its key platforms and strategic partnerships [1][4][8] - The company has shown resilience with an 8.9% stock gain over the past year, outperforming the industry [2] - QIAGEN's favorable solvency, with substantial cash reserves and low current debt, enhances its investment appeal [10] Growth Drivers - QIAGEN is expanding its test menu, achieving six regulatory clearances for panels in the U.S. syndromic testing market within the last 10 months, including notable FDA-approved panels [4][8] - The introduction of QIAcuity Diagnostic and the launch of over 100 new digital PCR assays are set to enhance its offerings in cell and gene therapy [5][8] - Strategic collaborations with companies like Eli Lilly and AstraZeneca are aimed at developing innovative diagnostic solutions [5][6][9] Financial Performance - QIAGEN has a market capitalization of $10.39 billion and an earnings yield of 5%, significantly higher than the industry's -28.5% yield [2] - The Zacks Consensus Estimate for QIAGEN's 2025 earnings per share has increased by 0.8% to $2.34, with projected revenues of $2.34 billion, indicating a 7.3% year-over-year growth [13] Challenges - QIAGEN faces macroeconomic headwinds that could impact global sales, particularly in the Asia Pacific region due to ongoing economic challenges [11] - The company is contending with intense competition in the pre-analytical and assay technology markets, which are characterized by price sensitivity and customer loyalty to existing suppliers [12]

Adaptive Biotechnologies (ADPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individua ...

Core Insights - RetinalGenix Technologies Inc. has appointed Dr. Taimour Langaee as a scientific advisor to enhance its DNA GPS Pharmacogenetics initiatives aimed at optimizing personalized treatment pathways for retinal and systemic diseases [1][5] - Dr. Langaee brings over 20 years of experience in pharmacogenomics and precision medicine, overseeing genotyping, sequencing data processing, and clinical genetic association studies [2][3] - The company aims to integrate advanced retinal imaging with pharmacogenetics and AI to identify early signs of chronic diseases, thereby improving overall health management and reducing long-term healthcare costs [6][7] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by combining genetic screening, advanced imaging, and therapeutic development [9] - The company's proprietary technologies include High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™, which are designed to prevent blindness and detect physiological changes indicating future ocular and systemic diseases [9] Strategic Goals - The integration of Dr. Langaee's expertise is expected to accelerate the company's efforts in delivering personalized, data-driven solutions for retinal and systemic health [5] - RetinalGenix's approach includes remote monitoring and personalized risk assessments based on genetic profiles, which aims to maximize the effectiveness of preventive strategies [7][8]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 通过构建一组肺癌患者队列，研究团队证明了在抗 PD-1 （αPD1） 治疗下 GLI 模型的响应能够精确反映相 应患者的免疫治疗结果。 此外，研究团队通过功能多组学分析， 在 GLI 模型中剖析了由外周血单个核细胞 （PBMC） 来源的 T 细胞 介导的各种肿瘤免疫过程，并对具有效应记忆样表型 （GNLY + CD44 + CD9 + ） 的循环肿瘤反应性 T 细胞 进行了表征，将其作为免疫治疗效果的潜在指标。 破译 肿瘤微环境 和 系统免疫宏观环境 之间的相互作用，对于开发更有效的癌症诊断和治疗策略至关重要。 2025 年 6 月 12 日，清华大学生物医学工程学院 刘鹏 副教授、 北京航空航天 大学生物与医学工程学院 陈晓芳 副教授、 北京大学人民医院 杨帆 教授团队合作，在 Cell 子刊 Cell Stem Cell 上发表了题为 ： An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer 的研究论文。 该研究开发了一种 类器官共培养模型—— 凝胶- ...